Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Semaglutide in Type 2 Diabetes and Peripheral Arterial Disease
NCT04560998Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Jun 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), Peripheral Arterial Disease (PAD), sponsored by Novo Nordisk. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT04560998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560998.